Publication: Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma
Program
KU-Authors
Bilir, Esra
KU Authors
Co-Authors
Zwimpfer T.A., Ewald H., Jayawardana M., Appenzeller-Herzog C., Bizzarri N., Razumova Z., Kacperczyk-Bartnik J., Heinzelmann-Schwarz V., Friedlander M., Bowtell D.D.L., Garsed D.W.
Advisor
Publication Date
Language
Type
Journal Title
Journal ISSN
Volume Title
Abstract
Objectives: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:. To evaluate the predictive value of the prognostic factor HRD status, as determined by various clinically validated HRD assays at the time of staging laparotomy, compared to BRCA1/2 mutation status for progression-free survival and overall survival in patients with tubo-ovarian high-grade serous carcinoma treated in the first-line setting with a combination of surgery and platinum-based chemotherapy and/or maintenance with PARP inhibitors. Copyright © 2024 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.
Source:
Cochrane Database of Systematic Reviews
Publisher:
John Wiley and Sons Ltd
Keywords:
Subject
Medicine